On September 15, 2020 Hangzhou Sumgen Biotech Co., Ltd. (hereinafter "Sumgen") reported the completing of a 220 million RMB series B funding led by Addor Capital, co-led by Cowin Capital and Sinowisdom, and jointly participated by BOCOM International, Haoshuo Investment, and Dynamic Balance Capital (Press release, Sumgen Biotech, SEP 15, 2020, View Source;a=nav&id=240 [SID1234656265]). This round of funding is primarily used for the R&D and industrialization of Sumgen’s innovative drugs. StartPointAdvisors served as the exclusive financial consultant for this funding round.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!